Vertex Pharmaceuticals (VRTX) Income from Non-Controlling Interests (2011 - 2018)

Vertex Pharmaceuticals' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$25.4 million for Q4 2018.

• In Q4 2018, Income from Non-Controlling Interests fell 1794.27% year-over-year to -$25.4 million; the TTM figure through Sep 2019 stood at -$25.4 million (down 248.38% YoY), while the FY2018 annual figure was -$9.8 million, up 94.3% from the prior year.
• Income from Non-Controlling Interests was -$25.4 million for Q4 2018 at Vertex Pharmaceuticals, down from -$290000.0 in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $28.4 million in Q2 2016 to a low of -$188.3 million in Q3 2017.
• Historically, Income from Non-Controlling Interests has averaged -$10.7 million across 5 years, with a median of -$98000.0 in 2015.
• The sharpest annual moves came in 2016 and 2017: Income from Non-Controlling Interests surged 5741.84% in 2016, then tumbled 26956.75% in 2017.
• A 5-year view of Income from Non-Controlling Interests shows it stood at $4.2 million in 2014, then sank by 122.39% to -$938000.0 in 2015, then slumped by 452.88% to -$5.2 million in 2016, then surged by 128.94% to $1.5 million in 2017, then tumbled by 1794.27% to -$25.4 million in 2018.
• The last three Income from Non-Controlling Interests figures came in at -$25.4 million (Q4 2018), -$290000.0 (Q3 2018), and -$1.1 million (Q2 2018), per Business Quant data.